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A B S T R A C T
Purpose: The aim of this study is to analyze the electroclinical features, treatment, and evolution of
patients with Rasmussen syndrome (RS).
Materials and methods: We conducted a retrospective, descriptive study in 32 consecutive patients with
RS followed between 1990 and 2012.
Results: Twenty boys and 12 girls were included in the study. The mean and median ages at onset of the
seizures were 6.5 and 7 years, respectively. Twenty-eight cases had epilepsia partialis continua that had
started at a mean age of 9.5 years. Fixed hemiparesis occurred within the ﬁrst two years after seizure onset
in 26 patients. The ictal EEG showed a multifocal origin, but conﬁned to the affected hemisphere in all
patients. Mild focal atrophy involved the temporo-insular region associated with enlargement of the
ipsilateral horn and Sylvian ﬁssure. An abnormal cortical and/or subcortical hyperintense signal was
observed in T2 and Flair images in 25 and 17 patients, respectively. T2 hyperintensity and atrophy in the
basal ganglia was documented in ﬁve patients. Corticosteroids associated with immunoglobulins were
used in 25 patients. Surgical treatment was performed in 25 patients. After a mean follow-up of 13 years
(range, 2–20) good surgical outcome – Engel class I – was observed in 23 of 25 patients operated.
Conclusion: Corticosteroid and intravenous immunoglobulin treatment should be considered in the
early stages of the disease. Patients with RS had a good response to surgical excision of the affected
hemisphere.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
In 1958, Rasmussen and co-workers reported three patients
suffering from focal seizures secondary to chronic localized
encephalitis.1 Today, most researchers and epileptologists still
use the term Rasmussen encephalitis or Rasmussen syndrome for
this particular condition.2–4 Here, we prefer to name the entity
Rasmussen syndrome (RS) in recognition of Rasmussen’s contri-
bution and because of the broader inclusiveness of the term
‘‘syndrome’’.
RS is a rare and severe immune-mediated brain disease which
results in unilateral brain atrophy leading to progressive neuro-
logical dysfunction and refractory seizures.1,4,5 Different mecha-
nisms have been suggested, but up to today the etiopathogenesis
has not been fully understood.6–10 The syndrome should be
considered sporadic, since there is no evidence supporting a
speciﬁc genetic marker.2,4
Recently the entity has been described as a distinctive constella-
tion based on speciﬁc lesions that are not exactly electroclinical* Corresponding author. Tel.: +54 11 4943 6116; fax: +54 11 4943 6116.
E-mail address: rhcaraballo@arnet.com.ar (R.H. Caraballo).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.02.003syndromes.11This is a diagnostically meaningful category of epilepsy
which may have therapeutic implications, particularly for surgery.
Most patients with RS are refractory to conventional antiepi-
leptic drugs (AEDs) and the only recommended therapeutic
approach is surgical hemispherectomy, which either removes
substantial parts of the affected hemisphere or disconnects the
hemispheres while removing a minimal amount of cortical
structures.12–15
Over the last years, important new knowledge has contributed
to our understanding of the pathophysiology, the diagnosis, and
the management of the condition.16 A consensus for the diagnosis
and therapy of RS, deﬁned at the 6th European Congress on
Epileptology in Vienna in 2004, has been published.4 Recently, Bien
et al.17 have found 3.3 new cases with RS in Germany per year.
The aim of this study is to analyze the electroclinical features,
treatment, and evolution of 32 patients with RS with a long-term
follow-up.
2. Materials and methods
We conducted a retrospective, descriptive study of 32
consecutive patients with RS followed between 1990 and 2012.
Mean time of follow-up was 11.5 years (range, 2–20 years)vier Ltd. All rights reserved.
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deﬁned by Bien et al. from the consensus group were considered.4
In our ﬁrst 13 patients, who were previously published,18 we used
the inclusion criteria according to Hart and coworkers.5
2.1. Inclusion criteria
A. Children who develop epilepsia partialis continua and meet at
least one of the following criteria to suggest the diagnosis of
chronic encephalitis: (1) progressive neurologic deﬁcit at the
beginning or after the onset of epilepsia partialis continua, but
before the start of treatment; (2) progressive hemispheric
atrophy on CT, MRI, or both, with or without density or signal
abnormalities; (3) presence of oligoclonal or monoclonal
banding; or (4) biopsy evidence of chronic encephalitis.
B. Children who do not have epileptic partialis continua but do
have focal epilepsy and biopsy evidence of chronic encephalitis.
They may, in addition, meet criteria 1, 2, or 3.5
Bien et al. have divided the criteria into two parts. RS is
diagnosed if either all three criteria of Part A or two out of three
criteria of Part B are present. We ﬁrst checked the features of Part A,
and if these were not fulﬁlled, features of Part B were taken into
account.
Part A
1. Clinical: focal seizures (with or without epilepsia partialis
continua) and unilateral cortical deﬁcits.
2. EEG: unihemispheric slowing with or without epileptiform
activity and unilateral seizure onset.
3. MRI: unihemispheric focal cortical atrophy and at least one of
the following: a hyperintense signal in the gray or white matter
on T2/Flair or a hyperintense signal in or atrophy of the
ipsilateral caudate head.
Part B
1. Clinical: epilepsia partialis continua or progressive* unilateral
cortical deﬁcits.
2. MRI: progressive* unihemispheric focal cortical atrophy.
3. Histopathology: T-cell-dominated encephalitis with activated
microglial cells (typically, but not necessarily, forming nodules).
Numerous parenchymal macrophages, B cells, or plasma cells or
viral inclusion bodies exclude the diagnosis of RS.
* Progressive means that at least two sequential clinical
examinations or MRI studies are required to meet the respective
criteria. To indicate clinical progression, each of these examina-
tions must document a neurological deﬁcit, and this must increase
over time. To indicate progressive hemiatrophy, each of these MRIs
must show hemiatrophy, and this must increase over time.
In addition, if no biopsy is performed, MRI with administration
of gadolinium and brain CT scan should be performed to document
the absence of gadolinium enhancement and calciﬁcations to rule
out the differential diagnosis of a unihemispheric vasculitis.19
Other immune-mediated epileptic encephalopathies, cerebral
vasculitis including lupus erythematosus, subacute measles
encephalitis with or without immunodeﬁciency, hemiconvul-
sion–hemiplegia–epilepsy syndrome, focal cortical dysplasia
including hemimegalencephaly, tumor, stroke, Sturge–Weber
syndrome, and neurometabolic diseases particularly mitochon-
driopathies, were excluded. Most of these entities may be
associated with epilepsia partialis continua (EPC).
In this study all patients underwent video-EEG in addition to
the routine EEG recordings. Evoked potentials, repeated brain CT
scans, and MRIs with or without gadolinium were obtained in allpatients. Magnetic resonance spectroscopy was performed in two
patients. Neurometabolic studies, especially to rule out mitochon-
drial disease, were also performed in all cases. CSF studies
including oligoclonal bands were performed in 17 patients, and
a measles antibody test was done in ﬁve. Other studies, such as
liver function, and blood and autoantibody tests, were done.
Antibodies against the N-methyl-D-aspartate receptor (NMDAR)
and mitochondrial DNA genetic testing for mutations were done in
four and two patients, respectively. Brain biopsy was performed in
four patients. Data on school achievements and neuropsychologi-
cal evaluations (Terman–Merrill or WISC III or IV) were repeatedly
obtained during the follow-up of 2–20 years. In the cases in which
formal neuropsychological tests could not be performed, cognitive
changes were evaluated based on clinical judgment.
Biochemical tests and urine analysis were performed, and
plasma levels of classic AEDs were monitored. The AEDs as well as
other treatment options, such as steroids, immunoglobulins, the
ketogenic diet, plasmapheresis, and surgical interventions, were
analyzed.
Determination of efﬁcacy of AED, corticosteroid, or immuno-
globulin treatment, as well as non-pharmacological therapy was
based on electroclinical criteria. Response to medical treatment
was evaluated according to the percentage of the seizure control
(seizure-free, 75–99% of seizure control, 50–74% seizure control,
and less than 50% seizure control). Surgical treatment was
evaluated according to the Engel classiﬁcation.20
3. Results
3.1. General characteristics
A total of 32 children (20 boys and 12 girls) with RS were
identiﬁed between March 1990 and June 2012 at the Garrahan
Hospital of Buenos Aires, Argentina. We did not ﬁnd any signiﬁcant
family history of febrile seizures and/or epilepsy. One patient had a
personal history of febrile seizures.
Sixteen patients (50%) had a history of infectious disease
previous to epilepsy onset. In 12 patients the infectious episode
had occurred two months before, and in four others three months
before the onset of the seizures.
Brain biopsy was compatible with RS in four patients, and
bilateral involvement was found in two of them. The surgical
specimens showed abnormalities compatible with RS in 25
patients who underwent surgery. No patients with non-inﬂam-
matory pathology or dual pathology were found.
3.2. Clinical features
The mean and median ages at onset of the seizures were 6.5 and 7
years, respectively (range, 4–14 years). All of the patients had focal
motor seizures, with secondary generalization in 18 (56%); six
patients (18%) had somatosensory focal seizures, 10 patients (31%)
had generalized tonic seizures, and eight (12.5%) had complex focal
seizures. Simple focal seizures were always contralateral to the
affected hemisphere. Sixteen patients (50%) had focal motor status
epilepticus, and ﬁve patients (15.5%) had generalized status
epilepticus. Two patients (6%) had drop attacks. Twenty-eight cases
(87.5%) had EPC that had started at a mean age of 9.5 years (range, 6–
16 years). In three patients (9.5%) EPC was the ﬁrst manifestation,
associated with hemidystonic and hemidyskinetic movements in
one. EPC lasted between sixteen hours and three weeks.
3.3. Neurologic symptoms other than epilepsy
In the ﬁrst stages of the disease, hemiparesis was sometimes
secondary to Todd’s paresis, but became persistent, ﬂuctuating in
Fig. 1. Background activity shows delta–theta slow waves in the right hemisphere.
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deﬁnitive neurological deﬁcit (hemiparesis) occurred within the
ﬁrst year after onset of the seizures in 10 patients (31%), in the
second or third year after seizure onset in 16 patients (50%), and
more than three years after seizure onset in six patients (19%).
Severe hemiparesis lead four patients to become wheelchair
bound. Dysphasia and dysarthria were found in 12 patients (38%),
and cortical sensory loss and visual deﬁcits were observed in six
(18%) and seven (22%) patients, respectively.
Cognitive impairment and behavioral disturbances were other
neurological manifestations that were observed in all patients.
Irritability, hyperactivity, and emotional labiality were the most
frequent behavioral changes. In the ﬁrst three years after seizure
onset, the patients were found to have learning difﬁculties,
memory loss, and attention deﬁcits.Fig. 2. Interictal EEG shows frequent slow waves and spAt the time of surgery, between 2 and 10 years after disease
onset, the mean IQ was 56  10 (range, 40–80).
3.4. EEG ﬁndings
The background activity in the affected hemisphere showed
delta and theta slow waves and sleep disorganization at onset in all
patients (Fig. 1). Over time, the slow activities became bilateral, but
predominantly in the affected hemisphere in most patients. In the
early period, the interictal EEG showed focal epileptiform
abnormalities in one hemisphere in 18 patients (56%) (Fig. 2)
and multifocal abnormalities in 14 patients (44%). The multifocal
abnormalities were seen in one hemisphere in 12 patients. Over
time, the interictal EEG recordings showed further deterioration;
the epileptiform activity increased and started to involve theike discharges in the right fronto-temporal regions.
Fig. 3. Background activity shows slow theta waves and epileptiform discharges in the left hemisphere.
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localized focus in two patients (6%) and there were multifocal
epileptiform discharges in one hemisphere in 18 patients (56.5%),
multifocal spikes in one hemisphere associated with synchronic
bilateral spikes in three patients (9.5%), bilateral multifocal spikes
in ﬁve patients (15.5%), and multifocal epileptiform activity
associated with synchronic bilateral (Fig. 4) discharges in four
patients (12.5%). Some abnormal epileptiform activity had the
appearance of ictal-like or subclinical discharges.
The ictal EEG showed a multifocal origin, but conﬁned to the
affected hemisphere in all patients, except in two patients with
bilateral hemisphere involvement. The seizures were secondarily
generalized in 10 patients (31%). Isolated seizure onset in the
unaffected hemisphere additionally to the seizure onset in the
affected hemisphere was registered in only one of the 32 patients.
3.5. Neuroradiological ﬁndings
CT scan and MRI demonstrated progressive unilateral cerebral
atrophy in all patients. In the early stages of the disease, mild focalFig. 4. Interictal EEG recording shows synchatrophy involved the temporo-insular region associated with
enlargement of the ipsilateral horn and Sylvian ﬁssure in 25
patients (81%) (Fig. 5A and B). An abnormal cortical and/or
subcortical hyperintense signal in T2 and Flair images was
observed in 17 patients (53%). T2 hyperintensity and atrophy in
the basal ganglia, particularly in the caudate nucleus, were
documented in ﬁve patients (15.5%) (Fig. 6A and B). Atrophy of
the contralateral cerebellar hemisphere was observed in one
patient and of the entire cerebellum in another. Magnetic
resonance spectroscopy showed decreased N-acetyl-D-aspartate
signal intensity over the entire affected hemisphere in two
patients. Functional imaging was not done in any of the patients
in this series.
3.6. Laboratory tests
Neurometabolic studies in blood and urine were normal in all
cases. Cerebrospinal ﬂuid was normal in 18 patients (56%), a mild
increase in lymphocytes was found in 10 patients (31%), and
protein was increased in nine patients (28%). Oligoclonal bandsronic and asymmetric bilateral spikes.
Fig. 5. A and B normal T2-weighted images (TR/TE 5500/80 ms) at onset (A) and 14
months later (B); note progressive atrophy of the left frontoparietal cortex and
enlarged subarachnoid spaces.
Fig. 6. A and B T2-weighted images (TR/TE 5500/80 ms) showing normal axial slices
at the level of the Silvian ﬁssure in another patient at onset (A) and 24 months later
(B); note asymmetric Silvian ﬁssures with right enlarged subarachnoid spaces. Also
see T2 prolongation and atrophy of the homolateral striatum.
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other antibodies were not performed in our series of patients.
Antibodies against the N-methyl-D-aspartate receptor (NMDAR)
were not found in four and mitochondrial DNA genetic testing for
mutations did not show abnormalities in two patients.
3.7. Treatment
The seizures were refractory to all different schemes of classic
and new AEDs used. None of the AEDs avoided progression of the
disease. High-dose prednisone (2–3 mg/kg/day) was indicated for
a period between 6 and 36 months in 30 patients, and intravenous
immunoglobulin, three days at 400 mg/kg/day administeredmonthly, was used in 29 patients for 6–24 months. Corticosteroids
associated with immunoglobulins were used in 25 patients for a
period of 6–24 months. A transient cessation of progression of the
neurological deterioration and a 25–75% seizure reduction was
observed in 14 of 25 patients receiving this combination; EPC
disappeared in 12 of 30 patients who received corticosteroids and
immunoglobulins alone or in combination.
Two patients received the ketogenic diet for 6 and 12 months,
respectively. In both patients a 50% seizure reduction was
Table 1
Differential diagnoses of Rasmussen syndrome.
(1) Non-progressive conditions
- Focal or hemispheric dysplasia
- Neoplasia
- Neurocutaneous syndromes
- Stroke
- Hemiconvulsion, hemiplegia and epilepsy syndrome
- Cerebral vasculitis in systemic disease (lupus erythematosus, Derry’s
vasculitis)
- Infective disorders (cat-scratch disease, HIV, others)
- Delayed-onset of subacute measles encephalopathy
- Other immune-mediated encephalitis (NMDAR antibodies)
(2) Progressive conditions
- Mitochondropathies (MELAS, POLG1, others)
- Lipofuscinosis
- Alpers disease
- Neuroaxonal dystrophy
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went vagus nerve stimulation and a 30% seizure reduction was
achieved after six months of follow-up. Other immunomodulatory
treatments, such as monoclonal antibodies, plasmapheresis, and
immunosuppressive drugs as well as antiviral treatments, were
not indicated in our series of patients. Five patients did not meet
the criteria for surgery, and two others refused surgical treatment.
Surgical treatment was performed after hemiparesis had become
ﬁxed in 25 patients: In 10 patients the modiﬁed Villemure
technique12 was performed, consisting of a peri-insular linear
corticectomy – preserving the operculum – until the lateral ventricule
is opened from the frontal to the temporal horn, followed by section of
the frontal horizontal ﬁbers, complete callosotomy, section of the
fornix, disconnection of the posterior temporal lobe and amygda-
lectomy. In 10 patients the classic Rasmussen technique13,15modiﬁed
with temporal lobe disconnection was performed, and hemispher-
otomy was performed in the remaining ﬁve patients.13
In this series of patients, extradural hematomata were observed
in two patients, an aseptic meningeal reaction occurred in two
other patients, and placement of a shunt was necessary in one
patient due to hydrocephalus.
3.8. Outcome
At the last control after a mean age of 13 years of follow-up
(range, 2–20 years), good surgical outcome – Engel class I – was
observed in 23 (92%) of 25 patients operated. Twenty of them were in
Engel class Ia, and the other three in Engel class Ib. In two of 25
patients who underwent surgery seizures continued; both had
bilateral electroclinical features and neuroradiological imaging of
brain involvement, and pathological ﬁndings compatible with RS.
Hemiparesis remained unchanged in all patients operated, except
the ﬁne ﬁnger movements, which deteriorated in ﬁfteen and
improved in two of 25 patients operated. All patients developed
independent gait after surgery. The outcome for visual ﬁelds
remained unchanged if already impaired or worsened following
surgery. After surgery, neuropsychological performance improved
in 10 children only. Seven patients showed dysphasia in the
immediate postsurgical period, which improved during follow-up.
Of the nine patients who had had preoperative behavioral problems,
seven improved signiﬁcantly after surgery and behavior remained
unchanged in two. All children who improved motor, neuropsycho-
logical, and behavioral performance had become seizure free.
Quality of life improved in all patients who became seizure free and
antiepileptic drugs could be reduced in all 25 patients after surgery.
The seven patients who did not undergo surgery continue
having refractory seizures. Four of them have not developed ﬁxed
hemiparesis yet and were not offered surgical treatment, and onehad bilateral brain involvement. The parents of two other patients
refused surgical treatment. Both patients who have shown to be
refractory to surgery also continue having seizures at 18 and 12
years of age after six and four years of follow-up, respectively.
4. Discussion
Here we present a series of 32 patients who fulﬁlled the
diagnostic criteria of RS with a long-term follow-up and who had a
good response to surgical treatment. Corticosteroid and intravenous
immunoglobulin treatments allowed for a transient cessation of
progression of the neurological deterioration and control of the
seizures including EPC. The presence of refractory unilateral focal
and multifocal seizures, EPC, and progressive neurological and
neuroradiological involvement of one hemisphere is suggestive of
RS. Early recognition is crucial to initiate adequate therapeutic
management of this severe epileptic syndrome. RS is the most
frequent progressive syndrome associated with EPC.
Formal diagnostic criteria for RS were ﬁrst proposed in 1994 by
Hart et al.5 Our group had the possibility to participate in this
interesting collaborative study. Subsequently, the European consor-
tium compounded these criteria with new data from advanced
neuroimaging techniques that better characterized the morpholog-
ical aspects of the disease.4 The clinical criteria proposed include a
two-step diagnostic approach: If the hallmark clinical, EEG, and
imaging criteria are fully met, the diagnosis may be established
without the need for a brain biopsy, however, if the criteria are not
fulﬁlled, the progression of clinical deﬁcits must be associated with
progressive hemispheric atrophy, as documented by sequential
MRIs or alternatively, by characteristic histopathological ﬁnd-
ings.4,21,22 It should be stressed that the progression of the
neurological deﬁcit and the worsening of unilateral brain damage
must be conﬁrmed in at least two sequential examinations, and
when the brain biopsy is not performed, MRI with gadolinium and
CT scan are required to rule out unihemispheric vasculitis. The last
inclusion criteria for the diagnosis of RS proposed4 are more
inclusive compared with the previous ones.5 Future discussion on
the inclusion criteria may be necessary in order to make them as
effective as possible for early diagnosis of the syndrome and
facilitate the planning of adequate medical and surgical treatment.
Finally, an accurate diagnostic work up should rule out all the
conditions characterized by unilateral neurological syndromes or
EPC, as well as inﬂammatory diseases mimicking RS.23
We found 32 consecutive patients with RS over 22 years (1.5
new patients per year) at our department. Although our center is
the only public hospital where these patients may be operated,
some patients are treated in a private setting and diagnosis of other
patients with RS may be missed. Thus, the incidence of RS found in
this study probably does not reﬂect the incidence of this particular
syndrome in Argentina, and a comparison with the incidence found
in Germany by Bien et al. may not be accurate.17
The management of this severe syndrome should include the
treatment of clinical manifestations and of the underlying
inﬂammation.4,5,24–26 According to the different clinical manifes-
tations and phases of the disease, the therapeutic strategy includes
both medical and surgical options. Additionally, treatment
alternatives must be taken into account according to the needs
of individual patients.27–31
Oral and intravenous corticosteroids are the most effective
medical treatment in terms of seizure control and neurological
deterioration, but long-term efﬁcacy has not been con-
ﬁrmed.5,17,21,25,26 Intravenous immunoglobulins have also been
reported to be effective in an important proportion of patients with
RS, improving seizure control and motor and cognitive altera-
tions.5,18,31 The use of a combination of corticosteroids and
immunoglobulins was also effective in the control of seizures and
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immunomodulatory treatments, such as rituximab, plasmaphere-
sis, tacrolimus, cyclophosphamide, azathioprine, antiviral drugs,
and interferon, have been reported.27–31 The efﬁcacy of these
treatment options has not been well elucidated yet, but they pose
new challenges. In the recent ﬁrst randomized prospective
treatment trial in patients with RS, tacrolimus or intravenous
immunoglobulins were shown to possibly slow down tissue and
function loss and prevent development of intractable epilepsy.17
It has been widely accepted that hemispherectomy and
hemispherotomy consisting in deafferentation of the hemisphere
with very limited tissue removal is effective in controlling seizures
as well as motor and mental deterioration in over 80% of
patients;12–15,32 in our series, results of surgery were good in
92% of the patients. Following surgery, most patients recover
partially from neurological deﬁcits, with a signiﬁcant improve-
ment in their quality of life.
Atypical forms of RS have been reported.33 Adolescent and adult
patients are increasingly being recognized and account for around
10% of the cases. This form is milder with more protected clinical
course. Seizures and motor and mental deterioration are less
severe than in typical childhood RS.34–36 In our series of 32
patients, seizures started at an adolescent age in two, but neither of
them had an atypical form. Persistently focal RS in adolescents and
adults without severe motor deﬁcits or episodes of EPC or status
epilepticus has also been reported,23,34–37 however, rare cases may
have a severe course similar to that of the childhood form.23 RS
with prominent basal ganglia involvement and predominant
movement disorders associated with hemiparesis and contralat-
eral brain MRI abnormalities has been described, and may lead to
misdiagnosis.4,22,23,38 We observed basal ganglia involvement in
only ﬁve patients. This may be due to the fact that when the ﬁrst
patients with RS were recognized, neuroradiological images were
of too low a resolution to detect this type of ﬁnding, and hence they
were not identiﬁed in this retrospective study.
Bilateral involvement of the brain in patients within the ﬁrst
months of the disease and in those with long-standing disease
probably due to a secondary epileptogenesis has been reported.39
We found bilateral involvement in two patients of our series.
Patients with RS associated with other pathologies, such as low-
grade tumors, cortical dysplasia, tuberous sclerosis, vascular
malformations and old ischemic lesions – a so-called double
pathology – have also been described.40–43 Clinical and imaging
ﬁndings resembling RS have recently been reported in patients
with gliomatosis, granulomatosis, and porphyria,44–49 however,
pathological evidence of their association is lacking.
At onset RS may be confused with a number of non-progressive
and progressive diseases with EPC and/or focal or unilateral brain
damage.18,23,50,51 The differential diagnoses of RS are listed in
Table 1.
5. Conclusion
We present a series of 32 patients who fulﬁlled the diagnostic
criteria of RS with a long-term follow-up.
Corticosteroid and intravenous immunoglobulin treatment,
alone or in combination, should be considered in the early stages of
the disease. These therapeutic alternatives allow for a transient
cessation of progression of the neurological deterioration and
control of the seizures including EPC, but almost all patients ﬁnally
undergo surgery.
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